Invented name: brand name of a medicinal product

The invented name is the brand name a medicine is authorised under; it must not be liable to confusion with the common name or with another medicine.

Also known as: brand name, trade name, proprietary name

4 min readUpdated

Reviewed by Gosia Luksza, CEO at Regunaut

At a glance

Legal basis
Article 1(20) of Directive 2001/83/EC; Article 6 of Regulation (EC) No 726/2004
Centralised
One single name for the whole EU, reviewed by EMA's Name Review Group
MRP, DCP, national
Each Member State assesses the name under its own guidance
Main test
No confusion in print, speech or handwriting with another medicine or the INN

How it works

Article 1(20) of Directive 2001/83/EC defines the name of a medicinal product as either an invented name not liable to confusion with the common name, or a common or scientific name accompanied by a trade mark or the name of the marketing authorisation holder. The common name is the international nonproprietary name (INN) recommended by the WHO or, where none exists, the usual common name. An invented name is therefore optional: a generic can be authorised as the INN followed by the company name. The name is part of the marketing authorisation. It opens section 1 of the SmPC, and Article 54(a) requires it on the outer packaging followed by the strength and pharmaceutical form, with the common name added where the product contains up to three active substances. Article 56a requires it in Braille.

For centrally authorised products, Article 6 of Regulation (EC) No 726/2004 requires each application to use a single name across the EU, otherwise than in exceptional cases relating to the application of the law on trade marks. Where a trade mark has been cancelled, opposed or objected to in a Member State, the Commission may accept a second name for that Member State if the holder documents its failed efforts. EMA's Name Review Group checks proposed names against its guideline on the acceptability of names. Mutual recognition, decentralised and national procedures have no single-name rule: each Member State assesses the name under its national guidance, so a product can carry different names in different countries, and the package leaflet lists the name used in each Member State.

The tests are similar everywhere. The name should not be liable to cause confusion in print, speech or handwriting with the name of another medicinal product, judged against the indication, patient population, pharmaceutical form, route of administration, strength and setting of use. It should not convey misleading therapeutic connotations, be misleading about the composition, pharmaceutical form or route, carry a promotional message, or be offensive or have an inappropriate connotation in an official EU language. It should not be derived from an INN or contain an INN stem, following World Health Assembly resolution WHA46.19. Qualifiers and abbreviations added to a name need an explanation. Regulatory acceptance is separate from trade mark registration: a registered mark can be refused as a medicine name, and an accepted name gives no trade mark rights. The guide to invented names for medicines walks through the review step by step.

What goes wrong

The name is chosen by marketing and trade mark counsel and reaches regulatory affairs after launch materials exist; it is cleared against trade mark registers but not against the names of medicines authorised nationally, which is where many similarity objections come from; it has a meaning or an unfortunate sound in one EU language; it contains an INN stem; a qualifier such as a single letter or number reads like a strength; and the product profile changes after acceptance, for example with a new indication or pharmaceutical form, so a name accepted for one profile is questioned for another. In a decentralised procedure a name accepted by the reference member state can still be refused by a concerned member state, which leaves the applicant looking for a second name for that market late in the procedure. A change of name after authorisation is a variation, and every carton, label and leaflet changes with it.

Timing

  1. From 18 months before the MAA

    Earliest point for a name review request to EMA, once eligibility for the centralised procedure is confirmed.

  2. NRG meeting

    Member States' objections are discussed and the CHMP adopts the outcome.

  3. 3 years

    Validity of an accepted name from CHMP adoption, extendable once by one year.

  4. 1 month before the CHMP opinion

    Latest point to tell EMA which accepted name the product will carry.

In the centralised procedure a name review request can be made no earlier than 18 months before the planned submission of the marketing authorisation application, once eligibility is confirmed. An accepted name stays valid for three years from adoption by the CHMP and can be reconfirmed once for a further year. The applicant must tell EMA which accepted name it will use at the latest one month before the CHMP opinion. In national, mutual recognition and decentralised procedures the name is proposed in the application and assessed by each Member State during the procedure, so a fallback name should be ready before submission.

What teams do with it in Regunaut

One job in the platform that turn on Invented name, each part of a wider workflow.

Invented name: common questions

Why are medicine names rejected by EMA?

Most rejections are for similarity: the name could be confused in print, speech or handwriting with a medicine already authorised centrally or in a Member State. Others fail because the name suggests a therapeutic effect or composition the product does not have, carries a promotional message, has an offensive or inappropriate meaning in an EU language, is too close to an INN or contains an INN stem.

Can a medicine have different brand names in different EU countries?

Yes, for products authorised nationally or through mutual recognition and decentralised procedures, where each Member State accepts the name separately. For centrally authorised products Article 6 of Regulation (EC) No 726/2004 requires a single name across the EU; the Commission may accept a second name only in exceptional cases where trade mark law blocks the name in a Member State.

Is an invented name the same as a trade mark?

No. A trade mark is an intellectual property right registered with a trade mark office. The invented name is the name the authority authorises the medicine under, judged on patient safety. A registered mark can be refused as a medicine name, and an accepted name gives no trade mark protection, so both clearances are needed before a name is used.

Does a generic need an invented name?

No. Article 1(20) of Directive 2001/83/EC allows the name to be the common name, normally the INN, accompanied by a trade mark or the name of the marketing authorisation holder, and many generics are authorised this way. In the centralised procedure that construction is also reviewed by the Name Review Group.

Guides that cover Invented name

Sources

  1. EUR-Lex: Directive 2001/83/EC on the Community code relating to medicinal products for human use
  2. EUR-Lex: Regulation (EC) No 726/2004 laying down Union procedures for the authorisation and supervision of medicinal products
  3. European Medicines Agency: Guideline on the acceptability of names for human medicinal products processed through the centralised procedure (EMA/CHMP/287710/2014 Rev. 7)

Put your Invented name question to Workbench

Workbench answers regulatory questions from EUR-Lex, EMA, national agencies and your own documents, with every claim linked to its source. Start free with welcome credits.